Table 2.

The predominant microbiota in the COVID-19 patients reported from current studies.

Type	Outcome	Ref
Acinetobacter, Chryseobacterium, Burkholderia, Brevundimonas, Sphingobium	The critical impact of mucosal microbiota on the susceptibility to SARS-CoV2 infection and severity of COVID-19 patients	[158]
Cutaneotrichosporon, Issatchenkia, Wallemia, Cladosporium, Alternaria, Dipodascus, Mortierella, Aspergillus, Naganishia, Diutina, and Candida
Firmicutes (42%), Bacteroidetes (25), Proteobacteria (18%), Actinobacteria (8%), and Fusobacteria (5%)	No statistically significant differences in nasopharyngeal microbiota of SARS-CoV-2 infection.	[144]
Acinetobacter (80.70%), Chryseobacterium (2.68%), Burkholderia (2.00%), Brevundimonas (1.18%), Sphingobium (0.93%), Mycobacterium (3.59%), and Prevotella (0.56%)	COVID-19 mortality is associated with complex mixed bacterial and fungal infections in the lungs, and microbiota monitoring is necessary in the lower respiratory tract for on-time personalized therapy.	[159]
Cutaneotrichosporon (Cryptococcus, 28.14%), followed by Issatchenkia (8.22%), Wallemia (4.77%), Cladosporium (4.67%), Alternaria (4.46%), Dipodascus (4.01%), Mortierella (3.22%), Aspergillus (2.72%), Naganishia (2.53%), Diutina (2.15%), and Candida (1.42%)